Evidence map›Paper›PMID 40778223›Full record

ArticleFrontiers in genetics2025

FEZF1-AS1 drives autophagy-mediated progression of colon cancer and reduces chemosensitivity through inhabiting the PI3K/AKT/mTOR signaling pathway.

Xiaoping Yang, Zuohui Yuan, Lingzhu Gou, Long Cheng, Zirui Wang, Pingfan Wu, Xiaochun Wang, Xueni Ma, Tiantian Ma, Yi Yu and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Xiaoping YangDepartment of Gastroenterology, Gansu provincial hospital, Lanzhou, China.
Zuohui YuanDepartment of Gastroenterology, Gansu provincial hospital, Lanzhou, China.
Lingzhu GouKey Laboratory of Digestive Diseases of Gansu Province, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Long ChengKey Laboratory of Digestive Diseases of Gansu Province, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Zirui WangDepartment of Urology, The Second People's Hospital of Lanzhou, Lanzhou, China.
Pingfan WuDepartment of Pathology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Xiaochun WangDepartment of Gastroenterology, Gansu provincial hospital, Lanzhou, China.
Xueni MaKey Laboratory of Digestive Diseases of Gansu Province, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Tiantian MaDepartment of Pneumology, Xi An Chest Hospital, Xian, China.
Yi YuDepartment of Gastroenterology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhiping WuDepartment of Gastroenterology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Dekui ZhangKey Laboratory of Digestive Diseases of Gansu Province, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathogenesis and chemoresistance mechanisms of colon cancer (CC) are still unclear. Here, we find that a long non-coding RNA (lncRNA), FEZ family zinc finger 1-antisense RNA 1 (FEZF1-AS1), is highly expressed in CC, which may be caused by the amplification mutation of FEZF1-AS1 at the gene level through bioinformatic analysis. FEZF1-AS1 has the potential to be a biomarker in the diagnosis of CC. Functionally, FEZF1-AS1 promotes the proliferation, invasion, metastasis, and survival of CC cells and reduces the sensitivity of CC cells to oxaliplatin. Mechanistically, FEZF1-AS1 drives autophagy-mediated development of CC and reduces chemosensitivity to oxaliplatin through inhabiting the PI3K/AKT/mTOR signaling pathway. In summary, our data suggest that FEZF1-AS1 may be a key driver of CC progression and chemotherapy resistance, and targeting FEZF1-AS1 may be a potential strategy for the diagnosis and treatment of CC.

Indexed as

autophagychemosensitivitycolon cancerFEZF1-AS1PI3K/AKT/mTOR

Identifiers

PMID40778223
PMCPMC12328158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.